The fastest-growing and largest of the 20 sized Pharmaceuticals markets in Malaysia, 2023 to 2033, with active clinical trials.
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Biosimilars | $59 Mn | $557 Mn | 25.1% | 7 |
| 2 | Cell Based Immunotherapy | $27 Mn | $215 Mn | 23.2% | 158 |
| 3 | Cannabidiol (CBD) | $36 Mn | $170 Mn | 17% | 0 |
| 4 | Cannabis | $55 Mn | $197 Mn | 13.7% | 0 |
| 5 | Atopic Dermatitis Drugs | $18 Mn | $58 Mn | 12.4% | 3 |
| 6 | Oncology/Cancer Drugs | $285 Mn | $649 Mn | 8.6% | 176 |
| 7 | Anti-Aging | $142 Mn | $315 Mn | 8.3% | 7 |
| 8 | Diabetes Management | $125 Mn | $254 Mn | 7.3% | 30 |
| 9 | Alzheimer Drugs | $8 Mn | $16 Mn | 7% | 1 |
| 10 | Contraceptives Drugs | $41 Mn | $80 Mn | 7% | 0 |
| # | Market | 2023 | 2033 (projected) | CAGR | Active trials |
|---|---|---|---|---|---|
| 1 | Oncology/Cancer Drugs | $285 Mn | $649 Mn | 8.6% | 176 |
| 2 | Anti-Aging | $142 Mn | $315 Mn | 8.3% | 7 |
| 3 | Diabetes Management | $125 Mn | $254 Mn | 7.3% | 30 |
| 4 | Gastrointestinal Drugs | $87 Mn | $139 Mn | 4.8% | 55 |
| 5 | Asthma & COPD Drugs | $80 Mn | $120 Mn | 4.2% | 9 |
| 6 | Biosimilars | $59 Mn | $557 Mn | 25.1% | 7 |
| 7 | Cannabis | $55 Mn | $197 Mn | 13.7% | 0 |
| 8 | HIV Drugs | $48 Mn | $86 Mn | 6% | 8 |
| 9 | Contraceptives Drugs | $41 Mn | $80 Mn | 7% | 0 |
| 10 | Cancer Supportive Care Drugs | $40 Mn | $64 Mn | 4.9% | 24 |
2033 values are projected from the 2023 size and the CAGR. Each market name opens its report. Active trials: recruiting, about to start or running.
Biosimilars grows fastest, at 25.1% a year from 2023 to 2033, ahead of Cell Based Immunotherapy (23.2%).
Oncology/Cancer Drugs is the largest, worth about $285 Mn in 2023 and $649 Mn by 2033 (projected).
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide.